Definium Therapeutics, Inc.
DFTX
$22.01
$0.854.02%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 57.58M | 48.64M | 45.29M | 38.20M | 36.92M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 193.37M | 166.31M | 151.19M | 130.32M | 113.87M |
| Operating Income | -193.37M | -166.31M | -151.19M | -130.32M | -113.87M |
| Income Before Tax | -237.54M | -183.79M | -168.10M | -114.52M | -77.63M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -237.54 | -183.79 | -168.10 | -114.52 | -77.63 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -237.54M | -183.79M | -168.10M | -114.52M | -77.63M |
| EBIT | -193.37M | -166.31M | -151.19M | -130.32M | -113.87M |
| EBITDA | -134.13M | -166.28M | -151.17M | -130.30M | -113.86M |
| EPS Basic | -2.49 | -2.06 | -1.97 | -1.36 | -0.95 |
| Normalized Basic EPS | -1.56 | -1.29 | -1.23 | -0.85 | -0.61 |
| EPS Diluted | -2.49 | -2.13 | -2.05 | -1.54 | -1.29 |
| Normalized Diluted EPS | -1.56 | -1.28 | -1.23 | -0.85 | -0.60 |
| Average Basic Shares Outstanding | 381.02M | 357.30M | 340.23M | 332.26M | 318.82M |
| Average Diluted Shares Outstanding | 381.02M | 359.33M | 342.26M | 336.61M | 326.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |